Dosedrugs Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.56 M
- Revenue Growth 29.44%
- Profit Growth -32.59%
- Ebitda 349.09%
- Net Worth 132.96%
- Total Assets 36.85%
About Dosedrugs Remedies
Dosedrugs Remedies Private Limited (DRPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 April 2017 (Seven years and ten months 5 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Corporate was formerly known as Dosedrug Remedies Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.56 M.
Atul Sutar and Rushikesh Sutar serve as directors at the Company.
Company Details
- Location
Kolhapur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909PN2017PTC170005
- Company No.
170005
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Dosedrugs Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Sutar  | Director | 20-Apr-2017 | Current |
| Rushikesh Sutar | Director | 14-Sep-2024 | Current |
Financial Performance of Dosedrugs Remedies.
Dosedrugs Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.44% increase. The company also saw a substantial fall in profitability, with a 32.59% decrease in profit. The company's net worth Soared by an impressive increase of 132.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dosedrugs Remedies?
Unlock access to Dosedrugs Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.56 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Dec 2022 | State Bank Of India | ₹0.56 M | Open |
How Many Employees Work at Dosedrugs Remedies?
Unlock and access historical data on people associated with Dosedrugs Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dosedrugs Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dosedrugs Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
